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Abstract
Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of
iron overload and the presence of chronic hepatitis C virus (HCV) infection. Effective iron chelation
therapy and HCV infection eradication may prevent liver complications. The European Association
for the Study of the Liver guidelines recommend interferon-free regimens for the treatment of HCV
infection in patients with hemoglobinopathies. However, data regarding the use of direct-acting anti-
viral drugs (DAAs) in this patient population are few. This observational study evaluated the safety
and efficacy of therapy with DAAs in an Italian cohort of patients with hemoglobinopathies, chronic
HCV infection and advanced liver fibrosis. Between March 2015 and December 2016, 139 patients
received DAAs and completed 12 weeks of follow up after the end of treatment for the evaluation
of sustained virological response (12SVR). The 12SVR (93.5%) was comparable with that typically
observed in cirrhotic patients without hemoglobinopathies. Three patients died during the period of
observation of causes unrelated to DAAs. One patient did not achieve a virological response and
five (3.6%) relapsed during 12 weeks of follow-up after the end of therapy. In addition, patients
showed significant reductions in serum ferritin at 12 weeks to levels similar to those observed in a
control group of 39 patients with thalassemia major without HCV infection, who adhered to chela-
tion therapy and had no overt iron overload. In conclusion, the use of DAAs appears to be safe and
effective in patients with hemoglobinopathies and advanced liver disease due to HCV.
1 | INTRODUCTION
Many patients with hemoglobinopathies have been infected with hepa-
titis C virus (HCV) through blood transfusion, mostly before screening
of blood donors was introduced in 1992. In the years immediately after
the HCV screening test became available, the prevalence of chronic
HCV infection among patients with thalassemia ranged from 4% in Tur-
key to 85% in Italy. Although the prevalence of HCV infection has
progressively decreased over the last 20 years, it is still higher than the
general population.1 Genotype 1b infection is the most frequent in
Italy. In epidemiological and cohort studies, the proportion of patients
with genotype 1b infection often exceeds 50%. Epidemiological data
on Italian patients with thalassemia and chronic HCV infection also
indicate that the prevalence of genotype 1b infection if more than
60%.1 HCV infection is associated with the risk of developing cirrhosis,
hepatocellular carcinoma and other liver complications, especially if left
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untreated.2–4 Cirrhosis has been reported in up to 32% of patients
with thalassemia5–9; these patients are at increased risk of death.10
Presence of chronic HCV infection and the extent of iron overload are
strong predictors of liver fibrosis progression.5,7,11
Effective chelation therapy and treatment of HCV infection are
needed in order to prevent liver complications and improve morbidity
and mortality.1,7,12 Pegylated interferon (peg-IFN) plus ribavirin (RBV)
has been the standard of care for the treatment of chronic HCV infec-
tion and cirrhosis.13 Studies of peg-IFN plus RBV have demonstrated sus-
tained virological response (SVR) rates of 25264% in patients with
thalassemia and HCV infection.14–17 However, peg-IFN and RBV are
both associated with anemia.13,15,18 The addition of RBV to peg-IFN sig-
nificantly increases the rate of SVR; however, in patients with thalasse-
mia, RBV-associated hemolysis leads to an increased requirement for
blood transfusions, which in turn can lead to worsening of iron
overload.1,14–16 Therefore, European Association for the Study of the
Liver (EASL) 2016 guidelines recommend interferon-free regimens for the
treatment of HCV infection in patients with hemoglobinopathies.13
Direct-acting antiviral drugs (DAAs) have demonstrated excellent
efficacy in patients with HCV infection, with SVRs of >90% reported,
irrespective of HCV genotype or response to previous therapy.3,19,20
However, DAAs have not been extensively used in patients with hemo-
globinopathies, and patients with hemoglobinopathies were excluded
from pivotal clinical trials of DAAs in chronic HCV infection.21 Current
clinical data regarding the safety and efficacy of DAAs in patients with
hemoglobinopathies and HCV infection are limited.21–24
The aim of this study was to evaluate the safety and efficacy of
DAA regimens in patients with hemoglobinopathies and chronic HCV
liver disease treated in Italy.
2 | METHODS
2.1 | Study design
Patients with hemoglobinopathies and HCV chronic disease from 11
thalassemia centers and who were treated with DAA regimens accord-
ing to the Italian Medicines Agency guidelines25 were included in the
“THAlassemia and hepatitis C Advance - Societa Italiana Talassemie ed
Emoglobinopatie” (ITHACA-SITE) dataset. The chart review was
approved by the Independent Ethics Committee at each participating
center, with the coordinating committee being located in Genoa, Italy.
All patients signed an informed consent to record their clinical and viro-
logical data in the database.
In the database, data were collected at baseline, at 4 weeks of
therapy, at the end of treatment and at 12 weeks of follow-up. Data
collected included levels of aspartate transaminase (AST), alanine trans-
aminase (ALT), serum creatinine, and quantitative serum HCV RNA.
Serum ferritin levels were evaluated at baseline and at 12 weeks of
follow-up after the end of therapy. Clinical data regarding diabetes, kid-
ney disease, heart disease, hypogonadotropic hypogonadism, hypothyr-
oidism, osteoporosis, presence of cryoglobulins, esophageal varices and
previous hepatocellular carcinoma were also recorded for each patient,
as well as data regarding current therapy, including iron chelation
therapy and previous antiviral therapy. All patients’ therapies were
assessed for potential drug—drug interactions between hepatitis drugs
and other medications.26 The number of transfused units per month
was recorded before, during and at the end of treatment. Cardiac and
hepatic iron overload was assessed with T2* magnetic resonance imag-
ing (MRI). Liver fibrosis was assessed before the start of DAA therapy
by FibroScan®(Echosens, Paris, France). A liver stiffness measurement
(LSM) 12 kPa was used as the cut-off for the diagnosis of cirrhosis.
2.2 | Patients
Patients included in the study had hemoglobinopathies with chronic
hepatitis due to HCV and the presence of fibrosis (defined as
Fibroscan® stiffness 10 kPa) or cirrhosis (defined as Fibroscan® stiff-
ness 12 kPa or through liver biopsy) determined within 6 months pre-
viously. Patients with extrahepatic manifestations of chronic HCV
infection (cryoglobulinemia with organ damage, B-lymphoproliferative
disorders) were also included. Patients with active cancer, including
hepatocellular carcinoma, and pregnant or lactating females were not
treated. A control group of patients with thalassemia major were also
included in the study. These patients were HCV-RNA negative, without
iron overload (according to MRI evaluation), and with compliance to
iron chelation therapy of >80%. Liver iron overload was defined as
MRI-T2* values less than 6.3ms and was categorized as mild (2.7-6.3
ms), moderate (1.4-1.6 ms), or severe (<1.4 ms).27
2.3 | Endpoints and outcomes measured
The primary endpoints of the study were to evaluate the efficacy and
safety of DAAs in patients with hemoglobinopathies and chronic hepa-
titis or cirrhosis due to HCV.
Outcomes measured included the SVR rate (i.e., the proportion of
patients with negative HCV RNA at week 12 of post-treatment follow
up), and the effect of treatment on liver enzymes (changes from base-
line in ALT, AST, and serum ferritin levels at the end of treatment and
at week 12 of follow up). Baseline was defined as within the 30 days
prior to receiving DAAs, and end of treatment was defined as 12 weeks
after initiation of treatment. Follow up was conducted 12 weeks after
the end of treatment (12-week follow up). Liver MRI-T2* evaluations
were performed within 6 months of commencement of therapy.
2.4 | Statistical analysis
Descriptive statistics were summarized as means6 standard deviation
(SD), medians, and percentages. To show the distribution of levels of
ALT, AST, and ferritin at baseline, at the end of the treatment, and at
12 weeks of follow up, boxplot graphs were used. The Shapiro–Wilk
test was used to test the normality of distributions. Changes in baseline
levels of ALT, AST, and ferritin were compared at the end of treatment
and/or after 12 weeks of follow up using the paired Wilcoxon test. The
Wilcoxon test (unpaired) was also used to compare ferritin measure-
ments between treated patients and the control group. Data were
manipulated using Excel (Microsoft, Seattle, WA, USA), and statistical
computing and graphics analyses were conducted using R software.28
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3 | RESULTS
3.1 | Patients
Between March 2015 and December 2016, 157 patients were included
in the ITHACA-SITE dataset. Of these, 139 (89%) met the study inclu-
sion criteria and completed therapy and 12 weeks of follow up. Patient
characteristics are summarized in Table 1. Mean (6SD) age was similar
in males (4166 years) and females (4468 years). The majority of
patients had thalassemia major (114 patients, 82%), 7 patients (5%)
were affected by sickle-cell thalassemia, 3 patients (2%) by thalassemia
intermedia and 1 patient (0.7%) by sickle-cell anemia. The most com-
mon HCV genotype was 1b (91, 65.5%). Almost all of the patients
(138/139) had a LSM >10 kPa (34.5% F2, 31.7% F3, 33.1% F4) and in
one patient cirrhosis was diagnosed histologically. More than half of
the patients (56.1%) failed a previous antiviral treatment course with
peg-IFN with or without RBV. By February 2017, all 139 patients
(100%) had completed treatment and their post-treatment follow-up.
The mean level of serum ferritin was 1,450 ng/mL (range: 103-
11,190 ng/mL) and liver iron overload was observed in 51 (37%)
patients. Of these, 33 (65%) patients had moderate iron overload, 12
(24%) had mild iron overload and 6 patients (12%) had MRI-T2* meas-
urements corresponding to moderate or severe liver iron overload.
The control group comprised 39 patients with thalassemia major.
The mean age (6SD) of the control group was 35 (69) years and the
majority was female (n525). All controls were HCV-RNA negative and
without iron overload (MRI-T2* >6.3 ms), with a mean ferritin level of
676 (6554) ng/mL (range 125–2537 ng/mL). The follow-up of the con-
trol group is greater than 24 months.
3.2 | Treatments
DAA therapy included sofosbuvir (SOF)-based regimens: SOF in
combination with RBV (9%), SOF plus daclatasvir (DCV) (20%), SOF
plus ledipasvir (LDV) with (9%) or without (38%) RBV, or SOF plus
simeprevir (SMV) with (2%) or without (10%) RBV; or ombitasvir
(OBV)/paritaprevir (PTV)-ritonavir plus dasabuvr (DBV) with (1%) or
without (12%) RBV. Table 2 presents the DAA regimens according to
HCV genotype.
The distribution of iron chelation regimens received by HCV
patients before and during antiviral therapy, as well as the median
doses administered, are reported in Supporting Information Table S1.
Chelation therapy was changed to deferoxamine in 41 (29%) patients
based on the previous studies of peg-IFN,1 which reported that oral
chelation therapy with deferoxamine was recommended for patients at
risk of leucopenia and some physicians preferred treatment with defer-
oxamine as a precaution due to the lack of drug interaction data avail-
able. Iron chelation therapy was not prescribed in one patient with
thalassemia major who had undergone allogeneic bone marrow trans-
plantation and in patients affected by other hemoglobinopathies.
Patients received a wide range of concurrent therapies during the
study. A description of concurrent therapies received by patients dur-
ing anti-HCV treatment (other than chelation therapy) can be found in
the Supporting Information Figure S1 and Table S2.
3.3 | Efficacy and safety
By intention-to-treat analysis, 136 patients (97.8%) achieved a
response at end of treatment, and 130 (93.5%) achieved a SVR. In addi-
tion to the three patients who died during therapy or follow-up, six
patients did not achieve HCV clearance. Five patients (one treated with
SOF plus SMV, one treated with SOF plus DCV and three treated with
SOF plus LDV) achieved virological response at the end of therapy and
experienced relapses during the 12-week follow-up, one of these six
patients did not achieve virological response on treatment with OBV/
PTV plus DBV and at the end of the therapy had an HCV-RNA serum
level of 20 IU/mL. These patients had increased levels of HCV-RNA
during the follow up. All of these patients were treated for 12 weeks
without RBV. SVR rates were high regardless of iron chelation therapy.
TABLE 1 Patient demographics and clinical characteristics
Patients
(n5139)
Age, years
Mean (6SD) 42 (67)
Range 30268
Gender, n (%)
Male 87 (63%)
Female 52 (37%)
Hemoglobinopathy, n (%)
Thalassemia major 114 (82%)
Thalassemia intermedia 13 (9%)
Sickle cell disease 12 (9%)
HCV genotype, n (%)
G1a 8 (5.8%)
G1b 91 (65.5%)
G2 25 (18.0%)
G3 7 (5.0%)
G4 7 (5.0%)
G5 1 (0.7%)
Liver2METAVIR Classification, n (%)
F2 48 (34.5%)
F3 44 (31.7%)
F4 46 (33.1%)
Comorbidities, n (%)
Heart disease 33 (24%)
Cryoglobulins 23 (17%)
Diabetes 20 (14%)
Kidney disease 5 (4%)
Previous antiviral treatment, n (%)
Peg-INF1 ribavirin 55 (40%)
Peg-INF 23 (17%)
None 61 (44%)
Liver iron overload, n (%)
Mild (MRI-T2* values 2.7-6.3 ms) 12 (24%)
Moderate (MRI-T2* values 1.4-1.6 ms) 4 (8%)
Severe (MRI-T2* values <1.4 ms) 2 (4%)
None 33 (65%)
HCV, hepatitis C virus; MRI, magnetic resonance imaging; peg-IFN, pegy-
lated interferon; SD, standard deviation.
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At 4 weeks 123/139 patients (88%) were HCV-RNA negative, 10/
139 patients (7%) remained HCV-RNA positive, while data for six
patients were missing. Figure 1 presents end of treatment virological
response rate and SVR rate in the treated patients by HCV genotype.
There were no significant alterations in renal function laboratory
measures. The blood transfusion requirement in the 3 months before
therapy, during the therapy and 3 months after DAA therapy did not
increase in patients who received DAA regimes without RBV (mean
blood units transfused 3.8 vs. 3.7 vs. 3.8, respectively); however, as
expected, the blood units requirement increased in patients treated
with RBV (mean blood units transfused 3.6 vs. 5.5 vs. 4.0, respectively,
P< .001).
Three patients died during treatment of causes unrelated to ther-
apy. A 59-year-old woman with sickle-cell anemia and a history of ane-
mia due to hematological disease died after 5 days of therapy with
SOF plus SMV due to a hemolytic crisis followed by heart failure and
cardiac shock. This death was unlikely to be related to treatment, as
hemolytic anemia has not been reported in the literature with either of
these antiviral drugs. A 36-year-old man with major thalassemia, diabe-
tes, hypothyroidism, hypogonadism and severe heart disease died from
secondary heart failure following bacterial sepsis. Finally, a 40-year-old
man with Child-Pugh C cirrhosis died 4 weeks after the end of antiviral
therapy died from liver failure after the appearance of a hepato-renal
syndrome. Also, no interference with chelation therapy was observed,
and no patients discontinued chelation therapy.
At the start of DAA treatment, only 29.2% of patients had normal
serum ALT, while 86.7% and 92% had normal ALT at the end of
treatment and 12 weeks thereafter, respectively. Reductions in
serum ALT levels from baseline were statistically significant both at the
end of treatment (P< .001) and at week 12 of follow up (P< .001;
Figure 2).
At baseline the mean (6SD) value of serum ferritin was 1450
(61660) ng/mL (range: 103211,190 ng/mL). The mean (6SD) value
of serum ferritin at the 12-week follow up after the end of treatment
was 1080 (61144) ng/mL (range: 8825696 ng/mL) among patients
who were HCV-RNA negative at Week 12 of treatment and the mean
reduction from baseline to Week 12 was statistically significant (433
ng/mL, P< .001; Supporting Information Figure S2).
In the comparison of treated patients and the control group of
patients without HCV infection and iron overload, mean baseline ferri-
tin levels were significantly higher in the treated versus control group
(mean difference: 773 ng/mL; P5.002), whereas at the 12-week follow
TABLE 2 Direct-acting antiviral regimens according to HCV genotype (total number of patients 139)
HCV genotype Patients(n)a
Regimen (n)
RBV 24 weeksbSOF1 SMV SOF1DCV SOF1 LDV OBV/PTV1DBV SOF1RBV
1a 8 1 6 1 3 3
1b 91 13 6 56 16 11 32
2 25 14 11 11 4
3 7 7 0 4
4 7 3 4 2 3
5 1 1 0 0
DBV, dasabuvir; DCV, daclatasvir; HCV, hepatitis C virus; LDV, ledipasvir; OBV, ombitasvir; PTV, paritaprevir; RBV, ribavirin; SMV, simeprevir; SOF,
sofosbuvir.
an: number of patients.
bDuration of the treatment.
FIGURE 1 End of Treatment Response (ETR) and Sustained Virological Response (SVR) in patients with hemoglobinopathies and chronic
HCV infection treated with DAAs
1352 | AJH ORIGA ET AL.
up, no statistically significant between-group differences were
observed (mean difference: 385 ng/mL; P5.21).
4 | DISCUSSION
This is the largest observational study of DAAs in patients with hemo-
globinopathies and HCV infection published to date. Until April 2017 in
Italy, the use of DAA-based regimens was restricted to patients with
advanced liver fibrosis or HCV-related severe extra-hepatic manifesta-
tions. Nevertheless, DAAs appeared to be safe and effective in this
patient population in the current study. Patients showed high treat-
ment response rates (SVR 93.5%), which were similar to those reported
in patients without hemoglobinopathies.3,19,20 Moreover, in our patient
cohort, no treatment-related adverse events responsible for premature
discontinuations were observed, and no overt drug-drug interactions
between iron chelators and antivirals were reported. The three deaths
that occurred during the observational period were due to complica-
tions of hematological or liver disease and not related to DAA therapy.
As expected, patients showed a significant reduction in serum liver
enzymes and ferritin. Moreover, ferritin levels in the treated patients at
the follow up 12 weeks after the end of DAA therapy were not signifi-
cantly different from those in the control group of patients with thalas-
semia without HCV infection or iron overload.
Our data confirm the finding of the multicenter phase III random-
ized trial of immediate or deferred treatment with elbasvir (EBR) plus
grazoprevir (GRZ) in 159 patients with HCV infection and inherited
blood disorders.22 In that study, patients with thalassemia, sickle cell
anemia, hemophilia A/B or von Willebrand disease were enrolled in 31
centers worldwide (US, Europe, Australia, Canada, Israel, and Thailand)
and treated with a 12-week course of EBR plus GRZ. Among 107
patients who received immediate treatment, an SVR was achieved by
93.5% of the patients. The rate of serious adverse events unrelated to
anti-HCV therapy was higher in patients who deferred treatment than
in those who received immediate treatment (11.5% vs. 2.8%), suggest-
ing an advantage of earlier treatment in these subjects.22
Higher SVR rates were reported in a smaller retrospective study of
81 patients with hemoglobinopathies (b-thalassemia major 86%, sickle
cell anemia/b-thalassemia 14%) and HCV infection (38%) treated at a
single institution in Greece between 2000 and 2015.21 In that study,
11 patients received treatment with DAAs. Nine of them had failed a
previous IFN-based course, and seven had severe fibrosis. All patients
achieved SVR, and ferritin levels appeared to be reduced in most
patients after treatment versus baseline.
Finally, in two case studies23,24 two patients with hemoglobinopa-
thies were successfully cured with SOF-based regimens. In the first
case study, a 51-year-old female patient with HbS b 0-thalassemia was
treated with SOF plus SMV, and achieved liver enzyme normalization,
without any signs of hemolysis or need for blood transfusion.24 In the
second case study, a 16-year-old male affected by sickle thalassemia
received 12 weeks’ of SOF plus PegIFN.23
During the IFN-era, patients with hemoglobinopathies and HCV
infection have largely been considered a “difficult-to-treat” population,
due to the coexistence of liver iron overload, often associated with
more advanced liver disease. The low response rates to IFN-based regi-
mens have also led to patients with thalassemia being perceived as “dif-
ficult to cure,” even with the newest DAA-based anti-HCV regimens.21
In our study, the significant reduction of liver enzymes and ferritin
associated with HCV elimination is clinically relevant, because they are
two confounding factors in the management of patients with hemato-
logical disease. The levels of ferritin were reduced to those observed in
a control group after HCV clearance. This may be due to the higher
chelating efficacy of drugs in the liver that is not affected by inflamma-
tion. This finding confirms that ferritin is a more reliable marker in the
monitoring of liver iron overload in patients without HCV infection.
Long-term measurements of serum ferritin and of the liver and heart
iron overload by MRI is needed to confirm this hypothesis. The
continuation of iron chelation therapy during treatment with DAAs
contributed to the reduction of ferritin. Most of our cohort of patients
was infected with HCV before the 1990s, hence the higher mean
age in the treated group of patients than in the control group. How-
ever, mean serum ferritin levels after treatment with DAAs were similar
to the younger control group. These results add further support
to EASL guidelines recommending the use of DAAs in selected
patients with comorbidities, with careful monitoring for drug–drug
interactions.13
The high number of enrolled patients, all followed for at least 3
months, is a particular strength of the study; it represents the largest
observational population studied to date in this setting. However, the
observational design is an obvious limitation of the current study.
Still, the use of RBV in patients with hemoglobinopathies infected
with HCV requiring complex oral combination therapy continues to
represent a treatment challenge since it is associated with a non-
negligible risk of hemolityc anemia, with increases in both ferritin val-
ues and the need for blood transfusions. However, the availability of
RBV-free regimens will further simplify the clinical management of this
subgroup of patients.
FIGURE 2 Median values and interquartile range (25th275th
percentile) of the ratio of the serum levels of alanine transaminase
(ALT) in respect to ALT normal levels at baseline, the end of
treatment, and week 12 of post-treatment follow up
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In conclusion, the use of DAAs appears to be safe and effective in
patients with hemoglobinopathies and cirrhosis or chronic hepatitis due
to HCV. Treatment with DAAs was associated with a significant reduc-
tion of liver enzymes and serum ferritin, two confounding factors in the
management of hemoglobinopathies. The lifetime utility of HCV eradi-
cation, in terms of reduction of liver complications and overall survival,
requires evaluation in long-term observational cohorts.
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